Biotech Values

[DewDiligence]

If the FDA grants interchangeable status on a given FoB product, a duopoly with high pricing and a substantial market share for BAX/MNTA will likely ensue, and you can model the sales and profits with some simple arithmetic.

If the FDA does not grant interchangeable status, I doubt that any of these FoB products will do more than a few hundred million in peak annual sales.